Event-Driven Stocks

NeuroPace Inc

NPCENasdaq

Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 4 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$100.0M$79.9M$65.4M$45.5M$45.2M$41.1M
Operating income−$16.3M−$21.7M−$27.2M−$40.8M−$23.7M−$13.1M
Net income−$21.5M−$27.1M−$33.0M−$47.1M−$36.1M−$24.3M
Total assets$105.6M$94.6M$107.7M$114.1M$133.6M$56.0M
Total liabilities$86.5M$86.6M$87.0M$79.3M$60.1M$62.4M
Equity$19.0M$8.0M$20.7M$34.8M$73.5M−$147.8M
EPS (diluted)$-0.66$-0.93$-1.27$-1.91$-2.17$-117.85
Shares out.32.6M28.3M25.1M24.5M24.5M314,096

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−16.3%
Net margin
−21.5%
Return on equity
−112.8%
Return on assets
−20.3%
Return on capital (ROCE)
−18.6%
Liabilities / assets
82.0%
Debt / equity
4.55×
Book value / share
$0.58
Revenue growth (YoY)
25.1%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-13.13distress
Accruals / assets
−9.9%clean
Beneish M-Score
-2.77normal
Piotroski F-Score
5/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
50
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 4 warning● 2 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026613,8172.3-20.7%
Apr 30, 2026773,8454.7-15.6%
Apr 15, 2026916,8116.6-3.4%
Mar 31, 2026948,7884.2+1.1%
Mar 13, 2026938,9633.2+16.6%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)